Articles

From Kinexum Founder - Ties that bind - People and Nations

How gratifying it is to see Kinexum’s growth in numbers of highly skilled professionals, scientific and clinical coverage, and geographic reach.  A reflection of Kinexum’s reach into the Asia Pacific region is the featuring of our own CEO, Thomas Seoh, in theWorld Korean Medical Journal[Click link to the article].  We are proud of Thomas and the many years of his experience as a successful entrepreneur, which led to this recognition.  Korea is an emerging force in the biotech and health product world.  What Korea has done in the electronics, consumer products, and auto industries will be followed by success in the life sciences industries.  Kinexum is in Korea now helping companies with pharmaceuticals, a cell therapy, and medical devices.  But, Korea is not an isolated example. Kinexum has long supported companies in China, India, Japan, and Australia.  As I write this, I am on the way to China to give a featured lecture at a symposium.  My first visit to China was in 1992 when assigned to the World Health Organization to help a pharmaceutical company in Shanghai.  How things have changed in China since then! 

 

Just as gratifying are the professionals who have become a part of Kinexum.  Many are friends and colleagues going back decades.  Perhaps my longest relationship is with Dr. Art Santora who has just joined us after a distinguished career at Merck.  Art is particularly special because he was singularly responsible for a career change that made all the difference in my life.  Art and I were medical school classmates at Emory.  He went straight to NIH to do his endocrine fellowship while I did mine at Vanderbilt.  I later joined him at NIH.  Art then moved up Rockville Pike to take a job in the Division of Metabolism and Endocrine Drug Products at FDA. Later, Art encouraged me to take a job that had opened up in that division.  I took the job thinking it would be a sabbatical, but long story short, it became a 12-year adventure of approving the first statin, metformin, the first insulin analog and other exciting therapies. FDA also sent me all over the world including to the WHO assignment in Geneva that took me to China. Without Art’s encouragement, I would probably still be studying intermediary metabolism at NIH and have seen very little of the world. Our careers are enriched by abiding relationships with individuals and peoples.  These relationships stretch over many years and countless miles.  It is these relationships that make us who we are more than anything that we may accomplish.